Introduction Etodolac was a popular nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and inflammation. In the United States, it was available in both prescription and over-the-counter forms and was widely prescribed by doctors. Unfortunately, in 2020, the Food and Drug Administration (FDA) announced the recall of Etodolac due to concerns over its safety. In this article, we will explore why this popular pain medication was discontinued and what this means for doctors and patients alike.
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that was used to treat mild to moderate pain and inflammation. It was available both as a prescription medication and as an over-the-counter medication. It was widely prescribed by doctors for a variety of conditions including arthritis, menstrual cramps, and other musculoskeletal conditions.
The FDA announced the recall of Etodolac in 2020 due to safety concerns. The FDA noted that the drug had been associated with an increased risk of serious cardiovascular events, including heart attack and stroke. Additionally, the FDA noted that the drug had been associated with an increased risk of gastrointestinal bleeding. As a result, the FDA determined that the risks associated with Etodolac outweighed the benefits and recommended that it be discontinued.
For doctors, the discontinuation of Etodolac means that they can no longer prescribe it to their patients. However, doctors can still prescribe other NSAIDs to treat pain and inflammation. Additionally, doctors should be aware of the potential risks associated with other NSAIDs and should only prescribe them when the benefits outweigh the risks. For patients, the discontinuation of Etodolac means that they may need to find an alternative medication to treat their pain and inflammation. Patients should speak to their doctor about other options that may be available to them. Additionally, patients should be aware of the potential risks associated with other NSAIDs and should only take them if the benefits outweigh the risks.
Etodolac was a popular nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and inflammation. Unfortunately, in 2020, the FDA announced the recall of Etodolac due to safety concerns. This means that doctors can no longer prescribe it to their patients and patients may need to find an alternative medication to treat their pain and inflammation. Doctors and patients should be aware of the potential risks associated with other NSAIDs and should only take them if the benefits outweigh the risks.
1.
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
2.
How artificial intelligence could significantly improve the prognosis for cancer patients.
3.
Children with the "Failure to Launch" Syndrome in Adulthood Have New Hope.
4.
Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.
5.
Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.
1.
Understanding Neutrophilia: Causes, Symptoms, and Treatment Options
2.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
3.
A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology
4.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
5.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation